Global ANGPTL3 ASPIRE; Pfizer GMG Competitive Grant Program

Convocatoria "abierta"
caduca en menos de 30 días
Entidad convocante:
Projectes de recerca
Plazo FSJD:
Up to $250.000

Call Objectives

Pfizer Global Medical Grants (GMG) support the global healthcare community's independent initiatives (research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Within the framework of the 'Global ANGPTL3 ASPIRE' Requests for Proposals, funding is available to support basic science, pre-clinical research and clinical research that advances medical knowledge of the role of ANGPTL3 in health and disease.

Call options

Innovative research may be in any of the following areas:

  • Role of ANGPTL3 in lipid/lipoprotein metabolism and relevance to ASCVD and pancreatitis o Elucidation of ANGPTL3 biology in health and disease. Examples may include but are not limited to:
    • Cellular and receptor interactions.
    • Inflammation/Immuno-inflammatory response.
    • Monocyte-macrophage biology.
    • Smooth muscle cell biology.
    • Lymphocyte biology.
    • Insulin resistance/pancreatic beta cells.
    • Adipose tissue.
    • Hepatic lipid metabolism/fatty liver/ectopic fat.
    • Pancreatitis.
    • Kidney/liver axis.
    • Blood-brain barrier/cognitive function.
    • Plaque biology.
  • ANGPTL3 genetics and gene regulation o ANGPTL3 in vascular biology/hematopoiesis.
  • Elucidation of ANGPTL3 biology in human disease. Examples may include but are limited to:
  • Atherosclerosis.
  • Infectious disease.
  • Renal disease.
  • Autoimmune and rheumatological diseases.
  • Type 2 diabetes.
  • Metabolic syndrome.

The following types of research projects are considered in scope and will be eligible for this programme:

  • Basic science, pre-clinical research and clinical research that aligns with the in-scope research topics (ie animal models, in vivo/in vitro studies).
  • Animal experimentation related to human biology.
  • Translational studies.


Individual projects requesting up to $250.000 will be considered. Pfizer anticipates a total fund of $750.000.



Eligible applicants must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. The applicant must be affiliated with a host institution. Only organisations are eligible to receive grants, not individuals or medical practice groups.

The geographic scope of this RFA is global.



Applications may be submitted through the online application system (see link below). The application process consists of two steps. First, a Letter of Intent must be submitted. Selected applicants are invited to submit a full application.

The deadlines are:

  • Letter of Intent: 12 March 2021.
  • Full Proposals: 2 July 2021.

In case of interest, please contact lnorton(ELIMINAR)